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Abstract: 
Adverse drug reaction (ADR) is widely concerned for public health issue. ADRs are one of 
most common causes to withdraw some drugs from market. Prescription event monitoring 
(PEM) is an important approach to detect the adverse drug reactions. The main problem to 
deal with this method is how to automatically extract the medical events or side effects from 
high-throughput medical events, which are collected from day to day clinical practice. In this 
study we propose a novel concept of feature matrix to detect the ADRs. Feature matrix, 
which is extracted from high-throughput medical data from The Health Improvement 
Network (THIN) database, is created to characterize the medical events for the patients who 
take drugs. Feature matrix builds the foundation for the irregular and high-throughput 
medical data. Then feature selection methods are performed on feature matrix to detect the 
significant features. Finally the ADRs can be located based on the significant features. The 
experiments are carried out on three drugs: Atorvastatin, Alendronate, and Metoclopramide. 
Major side effects for each drug are detected and better performance is achieved compared to 
other computerized methods. The detected ADRs are based on computerized methods, further 
investigation is needed.  
 
Keywords: adverse drug reactions, feature matrix, feature selection, drug interaction, 
Atorvastatin, Alendronate, Metoclopramide 
 
 
1.  Introduction 
Adverse drug reaction (ADR) is widely concerned for public health issue. ADRs are one of 
most common causes to withdraw some drugs from market [1]. Now two major methods for 
detecting ADRs are spontaneous reporting system (SRS) [2,3,4,5], and prescription event 
monitoring (PEM) [6,7,8,9,10]. The World Health Organization (WHO) defines a signal in 
pharmacovigilance as ³any reported information on a possible causal relationship between an 
adverse event and a drug, the relationship being unknown or incompletely documented 
previously´ [11]. For spontaneous reporting system, many machine learning methods are 
used to detect ADRs, such as Bayesian confidence propagation neural network (BCPNN) 
[12,13], decision support method [14], genetic algorithm [15], knowledge based approach 
[16,17], etc. One limitation is the reporting mechanism to submit ADR reports [14], which 
has serious underreporting and is not able to accurately quantify the corresponding risk. 
Another limitation is hard to detect ADRs with small number of occurrences of each drug-
event association in the database. Prescription event monitoring has been developed by the 
Drug Safety Research Unit (DSRU) and is the first large-scale systematic post-marketing 
surveillance method to use event monitoring in the UK [8]. The health data are widely and 
routinely collected.  It is a key step for PEM methods to automatically detect the ADRs from 
thousands of medical events. In paper [18, 19], MUTARA and HUNT, which are based on a 
domain-driven knowledge representation Unexpected Temporal Association Rule,  are 
proposed to signal unexpected and infrequent patterns characteristic of ADRs, using 
Queensland Hospital morbidity data, more commonly referred to as the Queensland Linked 
Data Set (QLDS) [20]. But their methods achieve low accuracies for detecting ADRs.  In the 
paper [21], four existing ADR detecting algorithms were compared by applying them to The 
Health Improvement Network (THIN) database for a range of drugs. The results show that 
the existing algorithms are not capable of detecting rare ADRs. Until now no successful 
algorithms are proposed to detect the ADRs automatically for PEM methods. 
In this paper we propose a novel approach using feature matrix to detect ADRs from The 
Health Improvement Network (THIN) database. First feature matrix which represents the 
medical events for the patients before and after taking drugs, is created by linking SDWLHQWV¶ 
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prescriptions and corresponding medical events together. Then significant features are 
selected based on feature selection methods, comparing the feature matrix before patients 
take drugs with one after patients take drugs. Finally the significant ADRs can be detected 
from thousands of medical events based on corresponding features. Experiments are carried 
on three drugs of Atorvastatin, Alendronate, and Metoclopramide. Good performance is 
achieved.  
2.  Feature matrix  
A novel concept of feature matrix is proposed to represent data and detect ADRs, using 
feature selection methods.  Normally patients take drugs for different periods of time, and 
have different numbers of repeated prescriptions. The longer the period of time, the more the 
medical events related to the drug. How to represent the high-throughput data related to 
prescriptions and medical events, is a key step to detect the ADRs. Feature matrix builds the 
basis of saving data and comparing data. Two kinds of feature matrix are built in this study, 
based on medical events using Readcodes at level 1-5 and Readcodes at level 1-3, 
respectively.  The medical events using Readcodes at level 1-3 give the general term, whereas 
those using Readcodes at level 1-5 give more specific descriptions.  
2.1 The THIN database 
The Health Improvement Network (THIN) is a collaboration product between two companies 
of EPIC and InPS. EPIC is a research organisation, which provides the electronic database of 
patient care records from UK and other countries. InPS continue to develop and supply the 
widely-used Vision general practice computer system. The anonymised patient data are 
collected from the practice's Vision clinical system on a regular basis without interruption to 
WKHUXQQLQJRIWKH*3¶VV\VWHPDQGVHQWWR(3,&ZKRVXpplies the THIN data to researchers 
for studies. Research studies for publication using THIN Data are approved by a nationally 
accredited ethics committee which has also approved the data collection scheme. 
7KHUHDUHµ7KHUDS\¶DQGµ0HGLFDO¶databases in THIN data. 7KH³7KHUDS\´GDWDEDVHFRQWDLQV
the details of prescriptions issued to patients. Information of patients and the prescription date 
for the drug can be obtained 7KH ³0HGLFDO´ GDWDEDVH FRQWDLQV D UHFRUG RI V\PSWRPV
diagnoses, and interventions recorded by the GP and/or primary care team. Each event for 
patients forms a record. By linking patient identifier, their prescriptions, and their 
corresponding medical events or symptoms together, feature matrix to characterize the 
symptoms during the period before or after patients take drugs is built. 
2.2 Readcodes and feature matrix 
Medical events or symptoms are represented by medical codes, named Readcodes. There are 
 W\SHVRIPHGLFDOHYHQWV LQ³5HDGFRGHV´GDWDEDVH7KH5HDG&RGHVXVHG LQJHQHUDO
practice (GP), were invented and developed by Dr James Read in 1982. The NHS (National 
Health Service) has expanded the codes to cover all areas of clinical practice. The code is 
hierarchical from left to right or from level 1 to level 5. It means that it gives more detailed 
information from level 1 to level 5.  Table 1 shows the medical symptoms based on 
5HDGFRGHVDWOHYHODQGDWOHYHOµ2WKHUVRIWWLVVXHGLVRUGHUV¶LVJHQHUDOGHVFULSWLRQXVLQJ
5HDGFRGHV DW OHYHO  µ)RRWSDLQ¶ µ+HHOSDLQ¶ HWF JLYe more details using Readcodes at 
OHYHO  µ2WKHU H[WUDS\UDPLGDO GLVHDVH DQG DEQRUPDO PRYHPHQW GLVRUGHUV¶ LV JHQHUDO WHUP
µ5HVWOHVV OHJV V\QGURPH¶ µ(VVHQWLDODQGRWKHU VSHFLILHG IRUPVRI WUHPRU¶HWF DUHGHWDLOHG
descriptions using Readcodes at level 5.  
In this research, two kinds of feature matrix are built to characterize the symptoms of patients 
who take drugs. One is based on Readcodes at level 1-5, which cover all the symptoms and 
detailed information which occur when patients take drugs. Another one is based on 
Readcodes at level 1-3, which is created by combining the detailed symptoms using 
Readcodes at level 4-5 into the general term using Readcodes at level 3. For the drug of 
$OHQGURQDWHµ7HPSRURPDQGLEXODU MRLQWGLVRUGHUV¶RIµ-¶DW level 4 is a typical ADR, 
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EXW µ'HQWRIDFLDO DQRPDOLHV¶ RI µ-¶ DW level 3 is more general term for this particular 
ADR. ,I SDWLHQWV KDYH WKH V\PSWRP RI µ7HPSRURPDQGLEXODU MRLQW GLVRUGHUV¶ µ-¶ LQ
feature matrix based Readcodes at 1-5, after we merge the detailed descriptions into the 
general term, a new feature matrix based on Readcodes at level 1-3 is rebuilt instead of using 
µ'HQWRIDFLDODQRPDOLHV¶µ-¶ 
2.3 The extraction of feature matrix 
To detect the ADRs of drugs, first feature matrix is extracted from THIN database, which 
describes the medical events that patients occur before or after taking drugs. Then feature 
selection methods of Student¶V t-test and Wilcoxon rank sum test are performed to select the 
significant features from feature matrix containing thousands of medical events.  Figure 1 
shows the process to detect the ADRs using feature matrix. Feature matrix A  (Figure 2) 
describes the medical events for each patient during 60 days before they take drugs. Feature 
matrix B  is one after patients take drugs. For repeated prescriptions, all the medical events 
related to each prescription of patients are input to build the feature matrix. When the interval 
between two adjacent prescriptions is less than 60 days, we put all the medical events 
between two adjacent into feature matrix after patients take drugs. When the interval between 
two prescriptions is more than 60 days, the medical events within 60 days after the first 
prescription are used build the feature matrix after patients take drugs, and the medical events 
beyond 60 days are put into the feature matrix before patients take drugs.  
In order to reduce the computation time and save the computation space, we set 100 patients 
as a group. Matrix X  and Y  are feature matrix after patients are divided into groups.   
Feature matrix A  and B  are defined as follows: 
njmiaA mxnij ,...,1,,...,1,0,)(     
}1,0{ija  
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where variable i  and j represent patients and medical events. Variable m and n represent the 
number of patients and medical events respectively. 1 ija  is for the state where ithpatient 
has jthmedical event; otherwise 0 ija . Feature matrix A and B describe the medical events 
during 60 days before or after patients take drugs.  
Feature matrix X  and Y  are defined as follows: 
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where variable g  represents the number of groups. Variable kjx represents the patient number 
of kth group having jthmedical event. In this study, each group contains 100 patients, and 
d is set to 100. 
 
3. Feature selection 
After two feature matrixes are obtained, which represent the medical events before and after 
patients take drugs, feature selection methods are performed to detect the significant features 
that reflect the significant changes. Feature selection methods normally have two classes. One 
FODVVLV³ZUDSSHU´PHWKRGVZKLFKVelect feature subsets based on classification performance, 
such as genetic algorithm [22, 23]. Another one is filter methods, which select features based 
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on between-class discriminant criterion, give the ranked features, and are not involved in 
classificatioQ SHUIRUPDQFH LQ WKH SURFHVV RI IHDWXUH VHOHFWLRQ VXFK DV 6WXGHQW¶V W-test and 
Wilcoxon rank-sum test.  
Obviously, in this study, it is not the classification problem. The main idea is to find which 
medical event changes significantly and give their ranks. We employ feature selection 
PHWKRGV RI 6WXGHQW¶V W-test and Wilcoxon rank-sum test, which are based on the data 
assumption having normal distribution and no assumptions for data distributions, respectively. 
%DVHG RQ GRFWRUV¶ VXJJHVWLRQ WKH UDWLR of the patient number after taking the drug to one 
before taking the drug for having one particular symptom is also used to represent the 
changes of symptoms. 
3.1 Student¶Vt-test 
6WXGHQW¶V t-test [24] feature selection method is used to detect the significant ADRs from 
thousands of medical events. 6WXGHQW¶Vt-test is a kind of statistical hypothesis test based on a 
normal distribution, and is used to measure the difference between two kinds of samples. 
6WXGHQW¶V t-test calculates a score jt to measure the difference between feature matrix X  and 
Y , which represents the importance of jth medical event or ADR among all groups of 
patients. 
6WXGHQW¶V t-test is defined as follows: 
y
yj
x
xj
jj
j
M
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M
S
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t
22

  nj ,...,2,1                      (1) 
where jx and jy represent the means of two groups of samples, xjS and yjS represent the 
standard deviations of two groups of samples. xM and yM represent the number of two groups 
of samples.  
3.2 Wilcoxon rank-sum test 
Student¶V t-test assumes that the data follow a normal distribution. If no assumption can be 
made about the shape of the population distribution, non-parametric statistical methods can 
be used. The Wilcoxon rank-sum test is a non-parametric analogue to 6WXGHQW¶V t-test for two 
independent samples. It is used for the determination of equality of the means of two non-
normal samples. The test is based on the rank of the individual data within feature matrix. As 
it operates on rank-transformed data, it also is a robust choice for detecting the significant 
medical symptoms. In this test, the ranking of data is performed first by giving the highest 
rank (equal to the number of features) to the feature with the highest value, and the lowest 
rank to the feature with lowest value. The ranks for remaining features are assigned using the 
rank-sum test as explained in details in [25]. 
3.3 Other parameters 
The variable of ratio 
1R is defined to evaluate significant changes of the medical events, using 
ratio of the patient number after taking the drug to one before taking the drug.  The variable 
2R  represents the ratio of patient number after taking the drug to the number of whole 
population having one particular medical symptom. 
The ratio variables 
1R and 2R  are defined as follows: 
°¯
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where 
BN and AN  represent the numbers of patients before or after they take drugs for having 
one particular medical event respectively. The variable N  represents the number of whole 
population who take drugs. 
We compare our proposed method with published results in [19]. Same evaluation standard is 
used in our research. Accuracy is defined as follows: 
alladr NNACC   
where ACC represents the accuracy to predict the ADRs. adrN  represents the number of true 
positive (ADRs), and allN  represents the number of whole number for prediction. In this 
research we only evaluate top 20  results of prediction, and allN is set to 20. 
 
4. Experiments and results 
Three drugs of Atorvastatin, Alendronate, and Metoclopramide are used to test our proposed 
method, using 20 GPs data in THIN database. 7KHGUXJRI$WRUYDVWDWLQLVRQHRIµVWDWLQ¶FODVV
DQG KDV WKH SDUWLFXODU µPXVFOH SDLQ¶ VLGH HIIHFWV )RU WKH GUXJ RI $OHQGURQDWH WKH
µ7HPSRURPDQGLEXODUMRLQWGLVRUGHUV¶LVDW\SLFDO$'57KHGUXJRIMetoclopramide has the 
typical ADR of µH[WUDS\UDPLGDOHIIHFWV¶RUµDEQRUPDOPRYHPHQWGLVRUGHUV¶ So in this study, 
three drugs that have different typical ADRs, are used to test our proposed method. Jin et al. 
also use the drugs of Atorvastatin and Alendronate to test their proposed methods of 
MUTARA and HUNT [18,19].  
Student¶V t-test and Wilcoxon rank-sum test are performed to select the significant features 
from feature matrix, which represent the medical events having the significant changes after 
patients take the drugs. In experiments, we use two kinds of feature matrix. One feature 
matrix is based on all medical events using Readcodes at level 1-5 in order to observe the 
detailed symptoms. Another one is based on the medical events using Readcodes at leve1 1-3, 
by combining the detailed information of Readcodes at level 4 and 5 into general terms using 
Readcodes at level 3.  
 
6RPHFRPPRQDEEUHYLDWLRQVXVHGLQWKHµ5HDGFRGHV¶GLFWLRQDU\DUHVKRZQas below: 
C/O      Complains of  
H/O History of  
NOS Not otherwise specified  
F/H  Family history  
O/E on examination  
[M] Morphology of neoplasms  
[D] Working diagnosis  
 
4.1 Atorvastatin 
Atorvastatin [26], under the trade name Lipitor, is one of the drugs known as statins. It is 
used for lowering blood cholesterol. There are seven currently prescribed forms of statin 
drugs. They are Rosuvastatin, Atorvastatin, Simvastatin, Pravastatin, Fluvastatin, Lovastatin, 
Pitavastatin. Muscle pain and musculoskeletal events are two of the main side effects of statin 
drugs [27]. 
Drugs.com provides access to healthcare information, sourced solely from the most trusted, 
well-respected and independant agents such as the Food and Drug Administration (FDA), 
American Society of Health-System Pharmacists, Wolters Kluwer Health, Thomson 
Micromedex, Cerner Multum and Stedman's. The side effects for Atorvastatin [28 ] by 
Drugs.com are severe allergic reactions (rash; hives; itching; difficulty breathing or 
swallowing; tightness in the chest; swelling of the mouth, face, lips, throat, or tongue); 
burning, numbness, or tingling; change in the amount of urine produced; confusion; memory 
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problems; mental or mood problems (eg, depression); muscle pain, tenderness, or weakness 
(with or without fever or fatigue); painful, difficult, or frequent urination; persistent pain, 
soreness, redness, or swelling of a tendon or joint; red, swollen, blistered, or peeling skin; 
severe stomach or back pain (with or without nausea or vomiting); symptoms of liver 
problems (eg, dark urine; pale stools; severe or persistent nausea, loss of appetite, or stomach 
pain; unusual tiredness; yellowing of the skin or eyes).  
We only use the data for patients, who registered on GP for more than one year, in order to 
obtain the reliable data. 6803 patients take Atorvastatin from 20GP data in THIN database. 
Based on Readcodes at level 1-5, totally 10528 medical events are obtained before or after 
6803 patients take the drug. So 6803x10528 feature matrix is obtained. Based on Readcodes 
at level 1-3, we combine the medical events which have the same first three codes into one 
medical event, just using first three codes. 10528 medical events based on Readcodes at level 
1-5 are combined into 2350 medical events based on Readcodes at level 1-3, and a 
6803x2350 feature matrix is created. After grouping patients, 68x10528 and 68x2350 feature 
matrix are formed to select the significant features, which reflect the significant change of 
medical events after patients take drugs. 
Table 2 and Table 3 show the top 20 ADRs for Atorvastatin based on 6WXGHQW¶V t-test and 
Wilcoxon rank-sum test, using medical events based on Readcodes at level 1-5 and level 1-3. 
From Table 2 and 3, it is clear that the detected ADRs are consistent with the published side 
effects for Atorvastatin. The difference for the detected ADRs between 6WXGHQW¶V t-test and 
Wilcoxon rank-sum test is that the rank of the ADRs is different. For example the medical 
HYHQWRIµ2WKHUVRIWWLVVXHGLVRUGHU¶LVrank 3 based on 6WXGHQW¶Vt-test, and rank 12 based on 
Wilcoxon rank-VXPWHVWµOther sRIWWLVVXHGLVRUGHU¶LVPDMRUVLGHHIIHFWIRUVWDWLQ)URPWKLV
view, the detected ADRs based on 6WXGHQW¶V t-test are better than those based on Wilcoxon 
rank-sum test.  
Our detected ADRs are classified into several categories, such as muscle pain, muscle 
weakness and neuropathy, gastrointestinal events, musculoskeletal events [27], skin and 
subcutaneous tissue events [28], bronchitis and bronchiolitis [29] diabetes mellitus events [30, 
31 ]. Good performance of 100% accuracy is achieved for the top 20 ADRs based on 
6WXGHQW¶Vt-test and Wilcoxon rank-sum test.  
MUTARA and HUNT [18,19] based on Unexpected Temporal Association Rule are 
proposed to signal unexpected and infrequent patterns characteristic of ADRs, using The 
Queensland Linked Data Set (QLDS). They indicated WKDW ³+817 FDQ UHOLably shortlist 
VWDWLVWLFDOO\VLJQLILFDQWO\PRUH$'5VWKDQ087$5$´)RUWKHGUXJRI$WRUYDVWDWLQ+817
detects 4 ADRs of µXULQDU\ WUDFW LQIHFWLRQ¶ µVWRPDFK XOFHU¶ µGLDUUKRHD¶ DQG µEURQFKLWLV¶
from top 20 results based on 13712 patient records, and only obtains 30% average accuracy 
[19]. The major side effects of Atorvastatin, such as muscle pain and musculoskeletal events, 
are not detected. Table 4 shows the performance of HUNT and MUTARA. Our proposed 
method detects µPXVFOHDQGPXVFXORVNHOHWDO¶HYHQWVQRt only based on Readcodes at level 1-
5, but also based on Readcodes at level 1-µ3HULSKHUDOHQWKHVRSDWKLHVDQGDOOLHGV\QGURPHV¶
DQGµ2WKHUVRIWWLVVXHGLVRUGHUV¶DUHGHWHFWHGDWUDQNDQGEDVHGRQ5HDGFRGHVDWOHYHO-3, 
using feature selection methoGRI6WXGHQW¶Vt-test. 
  
4.2 Alendronate 
Alendronate sodium, sold as Fosamax by Merck, is a bisphosphonate drug used for 
osteoporosis and several other bone disease [32]. The side effects for Alendronate [ 33] are 
severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; 
swelling of the mouth, face, lips, throat, or tongue); black, tarry, or bloody stools; chest pain; 
coughing or vomiting blood; difficult or painful swallowing; mouth sores; new, worsening, or 
persistent heartburn; red, swollen, blistered, or peeling skin; severe bone, muscle, or joint 
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pain (especially in the hip, groin, or thigh); severe or persistent sore throat or stomach pain; 
swelling of the hands, legs, or joints; swelling or pain in the jaw; symptoms of low blood 
calcium (eg, spasms, twitches, or cramps in your muscles; numbness or tingling in your 
fingers, toes, or around your mouth).   
In [32], side effects include ulceration of the esophagus, gastric and duodenal ulceration, skin 
rash, rarely manifesting as Stevens±Johnson syndrome and toxic epidermal necrolysis, eye 
problems (uveitis, scleritis),  generalized muscle, joint, and bone pain, osteonecrosis of the 
jaw or deterioration of the Temporomandibular Joint (TMJ), auditory hallucinations, visual 
disturbances. Studies suggest that users of alendronate have an increase in the numbers of 
osteoclasts and develop giant, more multinucleated osteoclasts. Fosamax has been linked to a 
rare type of leg fracture that cuts straight across the upper thigh bone after little or no trauma. 
3346 patients from 20GP data in THIN database are taking Alendronate, and 7260 medical 
events are obtained based on Readcodes at level 1-5. After grouping them, 33x7260 feature 
matrix is obtained. For Readcodes at level 1-3, 33x1964 feature matrix is obtained. Table 5 
and 6 show the top 20 ADRs based on 6WXGHQW¶V t-test and Wilcoxon rank-sum test. Our 
results show that most detected ADRs are consistent with the published results [32@µ&KURQLF
NLGQH\GLVHDVHVWDJH¶µ7\SHGLDEHWHVPHOOLWXV¶and µ(VVHQWLDOK\SHUWHQVLRQ¶DUHQRWOLVWHG
in [32]. 85% accuracy is achieved. But in [34], ¶DFXWH UHQDO IDLOXUH¶ LV UHSRUWHG DIWHU WKH
patient takes Alendronate. µBased on the study created by eHealthMe from U.S. Food and 
Drug Administration (FDA) and user community [35], 0.60SDWLHQWVKDYHµ7\SHGLDEHtes 
PHOOLWXV¶,Q>36], 0.62% patients KDYHµ(VVHQWLDOK\SHUWHQVLRQ¶ )RU+817RQO\µKHDGDFKH¶
µVZHOOLQJ¶ZKHH]H¶µEUHDWKLQJGLIILFXOW¶µKHDUWEXUQ¶DQGµFRQVWLSDWLRQ¶DUHGHWHFWHGLQWRS
20 ADRs based on 7569 patients.  Totally 30% average accuracy is obtained. The major side 
HIIHFWRIµPXVFOHRUMRLQWSDLQ¶LVQRWGHWHFWHG 
µPeripheral enthesopathies and allied syndromes¶DQGµOther soft tissue disorders¶with rank 
14 and 15 DUHGHWHFWHGWRGHVFULEHWKH$'5VUHODWHGWRµPXVFOHRUMRLQWSDLQ¶ZKLFK are listed 
in Table 5 using Readcodes at level 1-3 based on 6WXGHQW¶V t-test. But they are not list in 
Table 6 based on Wilcoxon rank-sum test in top 20 ADRs. From this view, 6WXGHQW¶V t-test 
method is better than Wilcoxon rank-sum test. 
After we obtain tKH UHVXOWVXVLQJ6WXGHQW¶s t-test with p<0.05, which reflect the significant 
changes after patients take drug, then we also sort the order of results according to 
descending order of  R1 value. Table 7 shows top 20 ADRs based on the descending order of 
R1 value. From Table 7, we notice WKDW WKH W\SLFDO VLGH HIIHFW µ7HPSRURPDQGLEXODU MRLQW
GLVRUGHUV¶IRU$OHQGURQDWH¶LVGHWHFWHGDWUDQN using Readcodes at level 1-5.  
 
4.3  Metoclopramide 
Metoclopramide is used to treat nausea and vomiting associated with conditions such as 
uremia, radiation sickness, malignancy, labor, infection, migraine headaches, and emetogenic 
drugs [37].  The side effects [38] for Metoclopramide are severe allergic reactions (rash; 
hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or 
tongue; unusual hoarseness); abnormal thinking; confusion; dark urine; decreased balance or 
coordination; decreased sexual ability; fast, slow, or irregular heartbeat; fever; hallucinations; 
loss of bladder control; mental or mood changes (eg, depression, anxiety, agitation, 
jitteriness); seizures; severe or persistent dizziness, headache, or trouble sleeping; severe or 
persistent restlessness, including inability to sit still; shortness of breath; stiff or rigid muscles; 
sudden increased sweating; sudden, unusual weight gain; suicidal thoughts or actions; 
swelling of the arms, legs, or feet; uncontrolled muscle spasms or movements (eg, of the arms, 
legs, tongue, jaw, cheeks; twitching; tremors); vision changes; yellowing of the skin or eyes. 
In [37] common adverse drug reactions associated with metoclopramide therapy include 
restlessness, drowsiness, dizziness, fatigue, and focal dystonia. Infrequent ADRs include 
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hypertension, hypotension, hyperprolactinaemia leading to galactorrhea, constipation, 
depression, headache, and extrapyramidal effects such as oculogyric crisis. 
8320 patients from 20 GPs take Metoclopramide. 8094 medical events are obtained using 
Readcodes at level 1-5, and 8320x8094 feature matrix is created. After 8094 medical events 
are combined into 2117 medical symptoms based on Readcodes at level 1-3, 8320x2117 
feature matrix is created. After patients are grouped, 83x8094 feature matrix is formed using 
Readcodes at level 1-5, and 83x2117 feature matrix is obtained using Readcodes at level 1-3. 
Table 8 and 9 show the top 2GHWHFWHGUHVXOWVLQDVFHQGLQJRUGHURISYDOXHRI6WXGHQW¶VW-
test and Wilcoxon rank-sum test, using Readcodes at level 1-5 and at level 1-3, respectively. 
From Table 8 and 9, it is shown that the typical side eIIHFWµ2WKHUH[WUDS\UDPLGDOGLVHDVHDQG
DEQRUPDOPRYHPHQWGLVRUGHUV¶for Metoclopramide is detected at rank 3 and rank 4 based on 
6WXGHQW¶V t-test and Wilcoxon rank-sum test. The top 20 medical events cover most important 
side effects for the drug of Metoclopramide. The side effect µ&KRODQJLWLV¶LVGHWHFWHGDWrank 
14 in Table 8 EDVHGRQ6WXGHQW¶s t-test using Readcodes at level 1-5. In [38], a 22-year-old 
female, treated with metoclopramide for 7 to 8 months for abdominal pain, developed hepatic 
hemangiomatosis with arteriovenous shunting and cholestasis.  
The ADRs having top ranks (rank 1,2,3,5) DUHµSDWLHQWGLHG¶ EDVHGRQ6WXGHQW¶VW-test using 
Readcodes at level 1-5, and they are not listed in [37, 38]. So our result achieves 80% 
accuracy. But based on the study created by eHealthMe from FDA and user community, 
1.93SDWLHQWVKDYH µ'HDWK¶ >39]. We notice that three patieQWVDUH µGLHG¶EHIRUH WKH\ WRRN
WKHGUXJ$FWXDOO\WKHUHDOVWDWHIRUWKHVHSDWLHQWVLVµH[SHFWHGGLHG¶ 
 
5. Discussion  
5.1 Feature matrix 
In this research, we propose the novel concept of feature matrix. For the medical data which 
are collected from day to day clinical practice, they are irregular and magnanimity data. Each 
patient has different medical information. Even for the same drug, different patients have 
taken drugs at different time points and different periods, and have different medical 
symptoms. How to extract the useful information after patients take drugs is first and key step 
to detect the adverse drug reactions. A novel concept of feature matrix is proposed to store 
and characterize the common information that only deal with symptoms before and after 
taking drugs for patients. For each drug, its corresponding feature matrix is built to cover all 
the symptoms or medical events occurred before or after taking the drug for all patients. 
Feature matrix transfer the unrelated information of different patients to common saving 
format, and build the foundation to detect the adverse drug reactions. For example, some 
SDWLHQWV WDNH WKH ³VWDWLQ´ GUXJV IRU \HDUV DQG WKH FRUUHVSRQGLQJ SUHVFULSWLRQV DQG PHGLFDO
HYHQWVDUH³PDVV´LQIRUPDWLRQ%XWZHRQly interest the information before and after taking 
drugs, feature matrix are built to characterize the representative features extracted from THIN 
database, which is collected day to day clinical practice. All the prescriptions during the 
period of taking drugs are checked. The medical events during 60 days before or after each 
prescription are used to build the feature matrix for this drug. This is reason that chronic side 
effects can be detected. For example, for the drug of Alendronate, one chronic side effect is 
³7HPSRURPDQGLEXODUMRLQWGLVRUGHUV´ZKLFKLVGHWHFWHGE\RXUSURSRVHGPHWKRG 
Two kinds of feature matrix are created to represents the medical events or symptoms for 
patients before and after taking drugs. One type of feature matrix is using original data based 
on Readcodes at level 1-5. Another one is based on Readcodes at level 1-3, combining the 
medical symptoms using Readcodes at level 4-5 into one using Readcodes at level 3. For 
H[DPSOHµ7\SHGLDEHWHVPHOOLWXV¶KDV5HDGFRGHVRIµ&)¶DWOHYHODQG5HDGFRGHVRI
µ&¶DWOHYHOUHSUHVHQWVWKHJHQHUDOWHUPRIµ'LDEHWHVPHOOLWXV¶ 
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5.2 The performance  
In this research, we compare our proposed method with published results in [19]. In paper 
[19], two drugs of Atovastatin and Alendronate are used to test their proposed methods, and 
average 30% accuracy is obtained in [19]. Their proposed methods do not detect two major 
side effects of muscle pain and musculoskeletal.  
Same evaluation standard is used in our research. Our proposed methods based on extracted 
feature matrix and feature selection achieve good results. For drug Atovastatin and 
Alendronate, major ADRs are detected, and 100% and 85% accuracy are obtained. For 
$WRUYDVWDWLQWKHPDMRUVLGHHIIHFWRIµPXVFOHSDLQ¶LVGHWHFWHGDWUDQNZKLFKLVµ2WKHUVRIW
WLVVXHGLVRUGHUV¶XVLQJ5HDGFRGHVDWOHYHO-3. For the drug of Alendronate, the typical side 
HIIHFWRIµ7HPSRURPDQGLEXODUMRLQWGLVRUGHUV¶LVGHWHFWHGDWUDQNEDVHGRQWKHGHVFHQGLQJ
order of the ratio of the patient number after taking the drug to one before taking the drug, 
ZKLFK LV µ'HQWRIDFLDO DQRPDOLHV¶ XVLQJ 5HDGFRGHV DW OHYHO -3. For the drug of 
0HWRFORSUDPLGH WKH W\SLFDO$'5RI µDEQRUPDOPRYHPHQWGLVRUGHUV¶ LVGHWHFWHGDW UDQN
ZKLFKLVµ2WKHUH[WUDS\UDPLGDOGLVHDVHDQGDEQRUPDOPRYHPHQWGLVRUGHUV¶XVLQJ5HDGFRGHV
at level 1-3.  
6WXGHQW¶V W-test assumes that the data follow a normal distribution. Wilcoxon rank-sum test 
has no assumption about the shape of data distribution. Experimental results show that 
StudeQW¶V W-test achieves better performance than Wilcoxon rank-sum test.  The variable of 
ratio of the patient number after taking the drug to one before taking the drug is 
FRPSOHPHQWDU\ SDUW IRU 6WXGHQW¶V W-test method. The ratio variable is useful to detect the 
some typical ADRs.  
Because of the creation of feature matrix, its unique saving format makes it possible to 
combine medical symptoms using Readcodes at level 4-5 into one using Readcodes at level 3. 
Feature matrix using Readcodes at level 1-5 give the detail information, and feature matrix 
using Readcode at level 1-3 can extract the general symptoms, which may be not noticed 
using feature matrix using Readcodes at level 1-IRUH[DPSOHWKH$'5RI³H[WUDS\UDPLGDO
GLVHDVHDQGDEQRUPDOPRYHPHQWGLVRUGHU´ for drug Metoclopramide.  
 
5.3 Rare ADRs, chronic ADRs, drug interaction, and advantages  
2XU SURSRVHG PHWKRG KDV VXFFHVVIXOO\ VKRUWOLVWHG WKH UDUH $'5V RI ³7HPSRURPDQGLEXODU
MRLQW GLVRUGHUV´ IRU GUXJ $OHQGURQDWH ³H[WUDS\UDPLGDO GLVHDVH DQG DEQRUPDO PRYHment 
GLVRUGHU´IRUGUXJ0HWRFORSUDPLGHDQGWKHUHVHDUFKZRUNLQ>@LQGLFDWHGWKDWWKHH[LVWLQJ
algorithms are not capable of detecting rare ADRs.  
The ADRs are rare, and it means the frequency to appear is low. If the methods detect the 
ADRs only based on the frequency of ADR appearing, there is never sufficient data to 
support the hypothesis of a causal relationship between the drug and the reaction.  
7KH UDUH $'5V RI ³7HPSRURPDQGLEXODU MRLQW GLVRUGHUV´ IRU GUXJ $OHQGURQDWH DQG
³H[WUDS\UDPLGDO GLVHDVH DQG DEQRUPDO PRYHPHQW GLVRUGHU´ IRU GUXJ 0HWRFORSUDPLGH DUH
from 3346 and 8320 patients. Enough data is used to support the detection of ADRs. Our 
proposed method is not only based on the frequency of ADR appearing, and but also is based 
on the significant change of medical symptoms. The rare ADRs may not appear frequently, 
but make the significant change. So our proposed method can detect rare ADRs. 
When feature matrix is built, all the prescriptions of each patient for this drug are checked to 
extract the information, no matter how long the patient takes this drug. Because of the 
characteristics of feature matrix, chronic medicine side effect can be detected. Exiting 
algorithms [18,19] only check the prescriptions during some period of time, and lose part of 
the information of side effects.  
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Because of the characteristics of feature matrix, it is easy to trace the information of patients 
having the particular ADRs, and extract the information of other drugs taken by these patients. 
This gives the foundation to do further research of drug interactions. 
Two advantages are achieved in this research compared with exiting algorithms. One is to 
propose feature matrix, which save the irregular information of each patient during whole 
period of taking drugs into standard saving format. This makes it possible to detect chronic 
ADRs. Another one is based on the changing degree of symptoms to detect the ADRs. This 
makes it possible to detect rare ADRs. 
 
6. Conclusions 
In this study we propose a novel method to successfully detect the ADRs by introducing 
feature matrix and feature selection to detect the significant changes after patients take drugs. 
A feature matrix, which characterizes the medical events before patients take drugs or after 
patients take drugs, is created from THIN database. Feature matrix transfers the irregular and 
high-throughput medical data collected from daily basis into feature matrix of standard 
saving format, and is a foundation to perform feature selection methods. Feature selection 
methods based on 6WXGHQW¶V t-test and Wilcoxon rank-sum test are used to detect the 
significant features from high dimensional feature matrix. The significant ADRs, which are 
corresponding to significant features, are detected. Experiments are performed on three drugs: 
Atorvastatin, Alendronate, and Metoclopramide. Compared to other computerized method, 
our proposed method achieves better performance. The detected ADRs are based on 
computerized methods, further investigation is needed.  
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Figure 1. The process to detect ADRs. Matrix A  and B  are feature matrix before or after patients take 
drugs. The time period of observation is set to 60 days. Matrix X  and Y  are feature matrix after 
patients are divided into groups. We set 100 patients as one group. 
 
 
 
Figure 2. Feature matrix. The row of feature matrix represents the patients, and the column of feature 
matrix represents the medical events. The element of events is 1 or 0, which represents that patients 
have or do not have the corresponding medical symptom or event.  
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Table 1 Medical events based on Readcodes at level 1-3 and level 1-5.  
7DEOH7KHWRS$'5VIRU$WRUYDVWDWLQEDVHGRQ6WXGHQW¶VW-test. 
Table 3 The top 20 ADRs for Atorvastatin based on Wilcoxon rank-sum test. 
Table 4 The accuracy of HUNT and MUTARA [19]. 
7DEOH7KHWRS$'5VIRU$OHQGURQDWHEDVHGRQ6WXGHQW¶VW-test. 
Table 6 The top 20 ADRs for Alendronate based on Wilcoxon rank-sum test. 
Table 7 The top 20 ADRs  for Alendronate based on the descending order of R1 value.  
7DEOH7KHWRS$'5VIRU0HWRFORSUDPLGHEDVHGRQ6WXGHQW¶VW-test.   
Table 9 The top 20 ADRs for Metoclopramide based on Wilcoxon rank-sum test.  
Table 10 The top 20 ADRs for Metoclopramide based on the descending order of R1 value. 
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Table 1 Medical events based on Readcodes at level 1-3 and level 1-5.  
 Level Readcodes Medical events 
 
Other soft  
tissue disorders  
 Level 3   N24..00  Other soft tissue disorders  
 
 
Level 5 
  N245.16  Leg pain  
  N245111  Toe pain  
  N241012   Muscle pain 
  N242000  Neuralgia unspecified  
  N241000  Myalgia unspecified 
 
Abnormal  
movement 
 Level 3 F13..00 Other extrapyramidal disease and abnormal movement disorders 
 
 
Level 5 
F13z200  Restless legs syndrome 
F131000 Benign essential tremor 
F131z00 Essential and other specified forms of tremor 
F132z12  Myoclonic seizure 
F132300  Myoclonic jerks 
 
 
7DEOH7KHWRS$'5VIRU$WRUYDVWDWLQEDVHGRQ6WXGHQW¶VW-test. 
 Rank Readcodes Medical events NB NA R1(%) R2 (%) 
 
 
 
 
Level 1-5 
1 1A55.00 Dysuria 26 181 6.96 2.66 
2 1Z12.00 Chronic kidney disease stage 3 63 477 7.57 7.01 
3 N131.00 Cervicalgia - pain in neck 73 337 4.62 4.95 
4 N143.00 Sciatica 48 205 4.27 3.01 
5 F4C0.00 Acute conjunctivitis 60 274 4.57 4.03 
6 N245.17 Shoulder pain 99 376 3.80 5.53 
7 M03z000 Cellulitis NOS 57 264 4.63 3.88 
8 1C14.00 "Blocked ear" 13 120 9.23 1.76 
9 A53..11 Shingles 17 121 7.12 1.78 
10 H01..00 Acute sinusitis 44 194 4.41 2.85 
11 1M10.00 Knee pain 103 369 3.58 5.42 
12 19EA.00 Change in bowel habit 17 102 6.00 1.50 
13 H06z000 Chest infection NOS 136 563 4.14 8.28 
14 C10F.00 Type 2 diabetes mellitus 154 436 2.83 6.41 
15 1D14.00 C/O: a rash 70 357 5.10 5.25 
16 M0...00 Skin and subcutaneous tissue infections 18 115 6.39 1.69 
17 N247100 Leg cramps 36 132 3.67 1.94 
18 M111.00 Atopic dermatitis/eczema 36 190 5.28 2.79 
19 19F..00 Diarrhoea symptoms 52 244 4.69 3.59 
20 H33..00 Asthma 23 106 4.61 1.56 
 
 
 
 
 
 
Level 1-3 
1 171..00 Cough 309 1105 3.58 16.24 
2 N21..00 Peripheral enthesopathies and allied syndromes 136 568 4.18 8.35 
3 N24..00 Other soft tissue disorders 462 1371 2.97 20.15 
4 1Z1..00 Chronic renal impairment 79 570 7.22 8.38 
5 1B1..00 General nervous symptoms 204 667 3.27 9.80 
6 19F..00 Diarrhoea symptoms 97 444 4.58 6.53 
7 M22..00 Other dermatoses 94 353 3.76 5.19 
8 1C1..00 Hearing symptoms 43 269 6.26 3.95 
9 183..00 Oedema 97 433 4.46 6.36 
10 N13..00 Other cervical disorders 81 362 4.47 5.32 
11 1B8..00 Eye symptoms 73 322 4.41 4.73 
12 F4C..00 Disorders of conjunctiva 85 381 4.48 5.60 
13 H06..00 Acute bronchitis and bronchiolitis 357 1161 3.25 17.07 
14 173..00 Breathlessness 198 675 3.41 9.92 
15 1A5..00 Genitourinary pain 56 276 4.93 4.06 
16 M03..00 Other cellulitis and abscess 73 357 4.89 5.25 
17 N09..00 Other and unspecified joint disorders 196 721 3.68 10.60 
18 1D1..00 C/O: a general symptom 159 695 4.37 10.22 
19 A53..00 Herpes zoster 20 158 7.90 2.32 
20 J57..00 Other disorders of intestine 48 222 4.63 3.26 
Variable NB and NA represent the numbers of patients before or after they take drugs for having medical events.  
Variable  R1 represents the ratio of the numbers of patients after taking drugs to the numbers of patients before 
taking drugs for having one particular ADR. Variable  R2  represents the ratio of the numbers of patients after 
taking drugs to the number of the whole population for having one particular ADR. 
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Table 3 The top 20 ADRs for Atorvastatin based on Wilcoxon rank-sum test. 
 Rank Readcodes Medical events NB NA R1(%) R2 (%) 
 
 
 
 
 
Level 1-5 
 1  1Z12.00           Chronic kidney disease stage 3      63     477    7.57      7.01 
  2  1A55.00                                  Dysuria      26     181    6.96      2.66 
  3  N131.00               Cervicalgia - pain in neck      73     337    4.62      4.95 
  4  M03z000                           Cellulitis NOS      57     264    4.63      3.88 
  5  C10F.00                 Type 2 diabetes mellitus     154     436    2.83      6.41 
  6  A53..11                                 Shingles      17     121    7.12      1.78 
  7  N143.00                                 Sciatica      48     205    4.27      3.01 
  8  F4C0.00                     Acute conjunctivitis      60     274    4.57      4.03 
  9  1C14.00                            "Blocked ear"      13     120    9.23      1.76 
 10  N245.17                            Shoulder pain      99     376    3.80      5.53 
 11  H01..00                          Acute sinusitis      44     194    4.41      2.85 
 12  K190.00 Urinary tract infection, site not specified      56     271    4.84      3.98 
 13  19EA.00                    Change in bowel habit      17     102    6.00      1.50 
 14  M0...00  Skin and subcutaneous tissue infections      18     115    6.39      1.69 
 15  M223.00                    Seborrhoeic keratosis      15      99    6.60      1.46 
 16  H33..00                                   Asthma      23     106    4.61      1.56 
 17  N245.13                                Foot pain      36     165    4.58      2.43 
 18  C34..00                                     Gout      66     194    2.94      2.85 
 19  G573000                      Atrial fibrillation      51     144    2.82      2.12 
 20  M21z100                                 Skin tag      14      86    6.14      1.26 
 
 
 
 
Level 1-3 
 1  1C1..00                         Hearing symptoms      43     269    6.26      3.95 
  2  1Z1..00                 Chronic renal impairment      79     570    7.22      8.38 
  3  H06..00       Acute bronchitis and bronchiolitis     357    1161    3.25     17.07 
  4  M03..00             Other cellulitis and abscess      73     357    4.89      5.25 
  5  N21..00 Peripheral enthesopathies and allied syndromes     136     568    4.18      8.35 
  6  J57..00             Other disorders of intestine      48     222    4.63      3.26 
  7  171..00                                    Cough     309    1105    3.58     16.24 
  8  A53..00                            Herpes zoster      20     158    7.90      2.32 
  9  173..00                           Breathlessness     198     675    3.41      9.92 
 10  M22..00                         Other dermatoses      94     353    3.76      5.19 
 11  K19..00 Other urethral and urinary tract disorders     101     496    4.91      7.29 
 12  N24..00              Other soft tissue disorders     462    1371    2.97     20.15 
 13  19F..00                       Diarrhoea symptoms      97     444    4.58      6.53 
 14  183..00                                   Oedema      97     433    4.46      6.36 
 15  F42..00                  Other retinal disorders      65     320    4.92      4.70 
 16  1B1..00                 General nervous symptoms     204     667    3.27      9.80 
 17  F4C..00                 Disorders of conjunctiva      85     381    4.48      5.60 
 18  1A5..00                       Genitourinary pain      56     276    4.93      4.06 
 19  H01..00                          Acute sinusitis      53     236    4.45      3.47 
 20  1B8..00                             Eye symptoms      73     322    4.41      4.73 
 
Table 4 The accuracy of HUNT and MUTARA [19]. 
               Experimental settings  Signalling accuracy   
  Drug Patients HUNT MUTARA 
 
Atorvastatin 
Older female  0.30 0.20 
Older male  0.30 0.20 
All patients (13712) 0.30 0.20 
 
Alendronate 
Older female  0.50 0.30 
Older male  0.40 0.20 
All patients (7569) 0.30 0.20 
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Table 5  The top 20 ADRs for Alendronate based on SWXGHQW¶VW-test. 
 Rank Readcodes Medical events NB NA R1(%) R2 (%) 
 
 
 
 
 
 
Level  
1-5 
1  1Z12.00           Chronic kidney disease stage 3      51     189    3.71      5.65 
  2  F4C0.00                     Acute conjunctivitis      30     125    4.17      3.74 
  3  M03z000                           Cellulitis NOS      37     152    4.11      4.54 
  4  1M10.00                                Knee pain      43     154    3.58      4.60 
  5  C10F.00                 Type 2 diabetes mellitus       7      44    6.29      1.32 
  6  H06z000                      Chest infection NOS      86     297    3.45      8.88 
  7  J16y400                                Dyspepsia      29     104    3.59      3.11 
  8  M0...00  Skin and subcutaneous tissue infections       9      65    7.22      1.94 
  9  182..00                               Chest pain      73     203    2.78      6.07 
 10  173I.00        MRC Breathlessness Scale: grade 2       9      43    4.78      1.29 
 11  N05..11                           Osteoarthritis      39     138    3.54      4.12 
 12  A53..11                                 Shingles      15      56    3.73      1.67 
 13  N131.00               Cervicalgia - pain in neck      48     132    2.75      3.95 
 14  G20..00                   Essential hypertension      30     116    3.87      3.47 
 15  1C14.00                            "Blocked ear"       5      39    7.80      1.17 
 16  1A55.00                                  Dysuria      21      76    3.62      2.27 
 17  F46..00                                 Cataract      14      67    4.79      2.00 
 18  K190.00 Urinary tract infection, site not specified      62     214    3.45      6.40 
 19  N143.00                                 Sciatica      33     103    3.12      3.08 
 20  AB2..12                                   Thrush      14      59    4.21      1.76 
 
 
 
 
 
 
 
 
 
Level  
1-3 
1  1Z1..00                 Chronic renal impairment      58     237    4.09      7.08 
  2  183..00                                   Oedema      77     252    3.27      7.53 
  3  C10..00                        Diabetes mellitus      16      77    4.81      2.30 
  4  H05..00 Other acute upper respiratory infections      50     217    4.34      6.49 
  5  173..00                           Breathlessness     127     386    3.04     11.54 
  6  M22..00                         Other dermatoses      43     181    4.21      5.41 
  7  171..00                                    Cough     161     472    2.93     14.11 
  8  19F..00                       Diarrhoea symptoms      64     225    3.52      6.72 
  9  1M1..00                       Pain in lower limb      49     172    3.51      5.14 
 10  F4C..00                 Disorders of conjunctiva      43     184    4.28      5.50 
 11  H06..00       Acute bronchitis and bronchiolitis     201     530    2.64     15.84 
 12  M03..00             Other cellulitis and abscess      46     181    3.93      5.41 
 13  AB0..00 Dermatophytosis including tinea or ringworm      22     102    4.64      3.05 
 14  N21..00 Peripheral enthesopathies and allied syndromes      52     154    2.96      4.60 
 15  N24..00              Other soft tissue disorders     229     573    2.50     17.12 
 16  168..00                        Tiredness symptom      67     217    3.24      6.49 
 17  19C..00                             Constipation      54     207    3.83      6.19 
 18  1A2..00                      Micturition control      15      75    5.00      2.24 
 19  1A1..00                    Micturition frequency      35     119    3.40      3.56 
 20  F56..00 Vertiginous syndromes, other disorders of vestibular system      19      79    4.16      2.36 
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Table 6 The top 20 ADRs for Alendronate based on Wilcoxon rank-sum test. 
 Rank Readcodes Medical events NB NA R1(%) R2 (%) 
 
 
 
 
 
Level 1-5 
 1  1Z12.00           Chronic kidney disease stage 3      51     189    3.71      5.65 
  2  M0...00  Skin and subcutaneous tissue infections       9      65    7.22      1.94 
  3  M03z000                           Cellulitis NOS      37     152    4.11      4.54 
  4  F4C0.00                     Acute conjunctivitis      30     125    4.17      3.74 
  5  G20..00                   Essential hypertension      30     116    3.87      3.47 
  6  1M10.00                                Knee pain      43     154    3.58      4.60 
  7  C10F.00                 Type 2 diabetes mellitus       7      44    6.29      1.32 
  8  K190.00 Urinary tract infection, site not specified      62     214    3.45      6.40 
  9  F46..00                                 Cataract      14      67    4.79      2.00 
 10  H01..00                          Acute sinusitis      21      78    3.71      2.33 
 11  A53..11                                 Shingles      15      56    3.73      1.67 
 12  J16y400                                Dyspepsia      29     104    3.59      3.11 
 13  182..00                               Chest pain      73     203    2.78      6.07 
 14  K15..00                                 Cystitis      45     131    2.91      3.92 
 15  N143.00                                 Sciatica      33     103    3.12      3.08 
 16  1D14.00                              C/O: a rash      49     184    3.76      5.50 
 17  H06z000                      Chest infection NOS      86     297    3.45      8.88 
 18  N05..11                           Osteoarthritis      39     138    3.54      4.12 
 19  N131.00               Cervicalgia - pain in neck      48     132    2.75      3.95 
 20  173I.00        MRC Breathlessness Scale: grade 2       9      43    4.78      1.29 
 
 
 
Level 1-3 
1  1Z1..00                 Chronic renal impairment      58     237    4.09      7.08 
  2  H05..00 Other acute upper respiratory infections      50     217    4.34      6.49 
  3  M22..00                         Other dermatoses      43     181    4.21      5.41 
  4  C10..00                        Diabetes mellitus      16      77    4.81      2.30 
  5  H06..00       Acute bronchitis and bronchiolitis     201     530    2.64     15.84 
  6  183..00                                   Oedema      77     252    3.27      7.53 
  7  M03..00             Other cellulitis and abscess      46     181    3.93      5.41 
  8  19F..00                       Diarrhoea symptoms      64     225    3.52      6.72 
  9  173..00                           Breathlessness     127     386    3.04     11.54 
 10  K19..00 Other urethral and urinary tract disorders      82     297    3.62      8.88 
 11  M0...00  Skin and subcutaneous tissue infections       9      65    7.22      1.94 
 12  171..00                                    Cough     161     472    2.93     14.11 
 13  G20..00                   Essential hypertension      35     130    3.71      3.89 
 14  AB0..00 Dermatophytosis including tinea or ringworm      22     102    4.64      3.05 
 15  F4C..00                 Disorders of conjunctiva      43     184    4.28      5.50 
 16  1M1..00                       Pain in lower limb      49     172    3.51      5.14 
 17  1A2..00                      Micturition control      15      75    5.00      2.24 
 18  1A1..00                    Micturition frequency      35     119    3.40      3.56 
 19  F4D..00                  Inflammation of eyelids      26      86    3.31      2.57 
 20  19C..00                             Constipation      54     207    3.83      6.19 
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Table 7 The top 20 ADRs  for Alendronate based on the descending order of R1 value.  
 Rank Readcodes Medical events NB NA R1 R2 
 
 
 
 
 
 
 
Level  
1-5 
1  F4K2100                      Vitreous detachment       1      23   23.00      0.69 
  2  N245.14                                Hand pain       1      20   20.00      0.60 
  3  K514.00       Uterovaginal prolapse, unspecified       0      18   18.00      0.54 
  4  16ZZ.00                      General symptom NOS       1      18   18.00      0.54 
  5  H040.00                         Acute laryngitis       1      17   17.00      0.51 
  6  N247012                        Swollen lower leg       0      17   17.00      0.51 
  7  1955.00                                Heartburn       1      17   17.00      0.51 
  8  F4C0311                               Sticky eye       1      17   17.00      0.51 
  9  M22z.12                         Seborrhoeic wart       1      17   17.00      0.51 
 10  S8z..13                               Laceration       1      16   16.00      0.48 
 11  J046.00        Temporomandibular joint disorders       0      14   14.00      0.42 
 12  173H.00        MRC Breathlessness Scale: grade 1       0      14   14.00      0.42 
 13  SE4..11                               Leg bruise       1      14   14.00      0.42 
 14  1B46.00                         C/O paraesthesia       1      14   14.00      0.42 
 15  G65..00             Transient cerebral ischaemia       1      14   14.00      0.42 
 16  1B16.11                       Agitated - symptom       1      14   14.00      0.42 
 17  1B6..13                        Vasovagal symptom       1      13   13.00      0.39 
 18  19A..00             Abdominal distension symptom       1      13   13.00      0.39 
 19  H32..00                                Emphysema       1      13   13.00      0.39 
 20  1AE..00                       Vaginal discomfort       1      12   12.00      0.36 
 
 
 
 
 
 
Level 
 1-3 
1  J04..00                    Dentofacial anomalies       0      16   16.00      0.48 
  2  BB5..00          [M]Adenomas and adenocarcinomas       1      16   16.00      0.48 
  3  A07..00 Intestinal infection due to other organisms       0      15   15.00      0.45 
  4  N35..00              Acquired deformities of toe       0      14   14.00      0.42 
  5  19A..00             Abdominal distension symptom       1      14   14.00      0.42 
  6  1M0..00                       Pain in upper limb       1      13   13.00      0.39 
  7  H32..00                                Emphysema       1      13   13.00      0.39 
  8  1J0..00                     Suspected malignancy       0      12   12.00      0.36 
  9  F11..00             Other cerebral degenerations       0      12   12.00      0.36 
 10  B22..00 Malignant neoplasm of trachea, bronchus and lung       1      12   12.00      0.36 
 11  1AE..00                       Vaginal discomfort       1      12   12.00      0.36 
 12  1CB..00                       Throat symptom NOS       2      22   11.00      0.66 
 13  A79..00                Specific viral infections       2      21   10.50      0.63 
 14  M0z..00     Skin and subcut tissue infection NOS       2      21   10.50      0.63 
 15  J02..00       Pulp and periapical tissue disease       1      10   10.00      0.30 
 16  B46..00           Malignant neoplasm of prostate       1      10   10.00      0.30 
 17  N36..00            Other acquired limb deformity       1      10   10.00      0.30 
 18  SE2..00                         Contusion, trunk       1       9    9.00      0.27 
 19  BB3..00                  [M]Basal cell neoplasms       1       9    9.00      0.27 
 20  15D..00                              Dyspareunia       0       9    9.00      0.27 
This table shows the top 20 results in descending order of R1 value for the detected rHVXOWVRI6WXGHQW¶VW-test with p<0.05. 
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7DEOH7KHWRS$'5VIRU0HWRFORSUDPLGHEDVHGRQ6WXGHQW¶VW-test.   
 Rank Readcodes Medical events NB NA R1(%) R2 (%) 
 
 
 
Level 1-5 
 1  22J..14                              Patient died       2     101   50.50      1.21 
  2  22J..12                                    Death       1      72   72.00      0.87 
  3  B590.00              Disseminated malignancy NOS       7      33    4.71      0.40 
  4  H25..00 Bronchopneumonia due to unspecified organism       5      22    4.40      0.26 
  5  22J..13                                     Died       0      41   41.00      0.49 
  6  1737.00                                 Wheezing       2      13    6.50      0.16 
  7  M0z..11                  Infected sebaceous cyst       2      11    5.50      0.13 
  8  1D11.00                          C/O: a swelling       1      10   10.00      0.12 
  9  E2B..00                  Depressive disorder NEC      34      73    2.15      0.88 
 10  G65..00             Transient cerebral ischaemia       4      15    3.75      0.18 
 11  1B16.00                                 Agitated       3      14    4.67      0.17 
 12  G573200           Paroxysmal atrial fibrillation       0       6    6.00      0.07 
 13  1A24.11            Stress incontinence - symptom       0       6    6.00      0.07 
 14  J661.00                              Cholangitis       0       6    6.00      0.07 
 15  C320.00               Pure hypercholesterolaemia       4      16    4.00      0.19 
 16  2841.00                                 Confused       5      18    3.60      0.22 
 17  F13z200                   Restless legs syndrome       3      12    4.00      0.14 
 18  173I.00        MRC Breathlessness Scale: grade 2       1       8    8.00      0.10 
 19  M101.00                   Seborrhoeic dermatitis       2      10    5.00      0.12 
 20  1732.00           Breathless - moderate exertion       0       7    7.00      0.08 
 
 
 
 
 
 
 
Level 1-3 
 1  22J..00                               O/E - dead       3     221   73.67      2.66 
  2  1C1..00                         Hearing symptoms      17      41    2.41      0.49 
  3  F13..00 Other extrapyramidal disease and abnormal movement disorders       6      22    3.67      0.26 
  4  H25..00 Bronchopneumonia due to unspecified organism       5      22    4.40      0.26 
  5  K20..00             Benign prostatic hypertrophy       2      14    7.00      0.17 
  6  A38..00                              Septicaemia       3      16    5.33      0.19 
  7  284..00                      O/E - disorientated      12      29    2.42      0.35 
  8  SK1..00                   Other specified injury      20      45    2.25      0.54 
  9  E2B..00                  Depressive disorder NEC      34      74    2.18      0.89 
 10  C32..00           Disorders of lipoid metabolism      13      34    2.62      0.41 
 11  H54..00      Pulmonary congestion and hypostasis       0       6    6.00      0.07 
 12  F48..00                      Visual disturbances       8      22    2.75      0.26 
 13  K16..00               Other disorders of bladder       3      12    4.00      0.14 
 14  M21..00 Other atrophic and hypertrophic conditions of skin       7      19    2.71      0.23 
 15  N23..00    Muscle, ligament and fascia disorders      10      23    2.30      0.28 
 16  B59..00   Malignant neoplasm of unspecified site      24      72    3.00      0.87 
 17  F46..00                                 Cataract      11      27    2.45      0.32 
 18  F4K..00                      Other eye disorders       4      14    3.50      0.17 
 19  1A2..00                      Micturition control      14      31    2.21      0.37 
 20  M2y..00 Other specified diseases of skin or subcutaneous tissue      10      23    2.30      0.28 
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Table 9 The top 20 ADRs for Metoclopramide based on Wilcoxon rank-sum test.  
 Rank Readcodes Medical events NB NA R1(%) R2 (%) 
 
 
 
 
 
 
 
 
 
Level 1-5 
1  22J..14                             Patient died       2     101   50.50      1.21 
  2  22J..12                                    Death       1      72   72.00      0.87 
  3  22J..13                                     Died       0      41   41.00      0.49 
  4  B590.00              Disseminated malignancy NOS       7      33    4.71      0.40 
  5  D00..00                 Iron deficiency anaemias      18      38    2.11      0.46 
  6  E2B..00                  Depressive disorder NEC      34      73    2.15      0.88 
  7  H25..00 Bronchopneumonia due to unspecified organism       5      22    4.40      0.26 
  8  E200300                  Anxiety with depression      20      44    2.20      0.53 
  9  F46..00                                 Cataract       9      23    2.56      0.28 
 10  G580.11               Congestive cardiac failure       7      19    2.71      0.23 
 11  C320.00               Pure hypercholesterolaemia       4      16    4.00      0.19 
 12  1B13.00                              Anxiousness      13      30    2.31      0.36 
 13  G65..00             Transient cerebral ischaemia       4      15    3.75      0.18 
 14  B10..00         Malignant neoplasm of oesophagus      10      22    2.20      0.26 
 15  M244.00                             Folliculitis       7      18    2.57      0.22 
 16  2841.00                                 Confused       5      18    3.60      0.22 
 17  1B16.00                                 Agitated       3      14    4.67      0.17 
 18  1737.00                                 Wheezing       2      13    6.50      0.16 
 19  M0z..11                  Infected sebaceous cyst       2      11    5.50      0.13 
 20  F13z200                   Restless legs syndrome       3      12    4.00      0.14 
 
 
 
 
Level 1-3 
 1  22J..00                               O/E - dead       3     221   73.67      2.66 
  2  1C1..00                         Hearing symptoms      17      41    2.41      0.49 
  3  C32..00           Disorders of lipoid metabolism      13      34    2.62      0.41 
  4  F13..00 Other extrapyramidal disease and abnormal movement disorders       6      22    3.67      0.26 
  5  B59..00   Malignant neoplasm of unspecified site      24      72    3.00      0.87 
  6  F46..00                                 Cataract      11      27    2.45      0.32 
  7  1A2..00                      Micturition control      14      31    2.21      0.37 
  8  N23..00    Muscle, ligament and fascia disorders      10      23    2.30      0.28 
  9  284..00                      O/E - disorientated      12      29    2.42      0.35 
 10  E2B..00                  Depressive disorder NEC      34      74    2.18      0.89 
 11  H25..00 Bronchopneumonia due to unspecified organism       5      22    4.40      0.26 
 12  SK1..00                   Other specified injury      20      45    2.25      0.54 
 13  F48..00                      Visual disturbances       8      22    2.75      0.26 
 14  M2y..00 Other specified diseases of skin or subcutaneous tissue      10      23    2.30      0.28 
 15  M21..00 Other atrophic and hypertrophic conditions of skin       7      19    2.71      0.23 
 16  K20..00             Benign prostatic hypertrophy       2      14    7.00      0.17 
 17  A38..00                              Septicaemia       3      16    5.33      0.19 
 18  K16..00               Other disorders of bladder       3      12    4.00      0.14 
 19  M10..00            Erythematosquamous dermatosis       9      20    2.22      0.24 
 20  Eu4..00 [X]Neurotic, stress - related and somoform disorders       8      18    2.25      0.22 
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Table 10 The top 20 ADRs for Metoclopramide based on the descending order of R1 value. 
 Rank Readcodes Medical events NB NA R1(%) R2 (%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1  22J..12                                    Death       1      72   72.00      0.87 
  2  22J..14                             Patient died       2     101   50.50      1.21 
  3  22J..13                                     Died       0      41   41.00      0.49 
  4  1D11.00                          C/O: a swelling       1      10   10.00      0.12 
  5  22J..00                               O/E - dead       0      10   10.00      0.12 
  6  A38..00                              Septicaemia       1       9    9.00      0.11 
  7  173I.00        MRC Breathlessness Scale: grade 2       1       8    8.00      0.10 
  8  L05..12                 Termination of pregnancy       1       8    8.00      0.10 
  9  19CZ.00                         Constipation NOS       1       8    8.00      0.10 
 10  1732.00           Breathless - moderate exertion       0       7    7.00      0.08 
 11  2225.00                         O/E - dehydrated       1       7    7.00      0.08 
 12  A54..00                           Herpes simplex       1       7    7.00      0.08 
 13  S8z..13                               Laceration       1       7    7.00      0.08 
 14  M18z.11                          Skin irritation       1       7    7.00      0.08 
 15  A38z.11                                   Sepsis       1       7    7.00      0.08 
 16  22K5.00            Body mass index 30+ - obesity       1       7    7.00      0.08 
 17  1737.00                                 Wheezing       2      13    6.50      0.16 
 18  G573200           Paroxysmal atrial fibrillation       0       6    6.00      0.07 
 19  1A24.11            Stress incontinence - symptom       0       6    6.00      0.07 
 20  J661.00                              Cholangitis       0       6    6.00      0.07 
 
 
 
 
 
 
 
 
Level 1-3 
1  22J..00                               O/E - dead       3     221   73.67      2.66 
  2  K20..00             Benign prostatic hypertrophy       2      14    7.00      0.17 
  3  H54..00      Pulmonary congestion and hypostasis       0       6    6.00      0.07 
  4  E13..00               Other nonorganic psychoses       1       6    6.00      0.07 
  5  K12..00            Calculus of kidney and ureter       1       6    6.00      0.07 
  6  A38..00                              Septicaemia       3      16    5.33      0.19 
  7  H21..00           Lobar (pneumococcal) pneumonia       1       5    5.00      0.06 
  8  K56..00        Noninflammatory vaginal disorders       1       5    5.00      0.06 
  9  SK03.00       Post-traumatic wound infection NEC       1       5    5.00      0.06 
 10  A3Ay200          Clostridium difficile infection       0       5    5.00      0.06 
 11  1CE..00                         C/O - wax in ear       1       5    5.00      0.06 
 12  H25..00 Bronchopneumonia due to unspecified organism       5      22    4.40      0.26 
 13  K16..00               Other disorders of bladder       3      12    4.00      0.14 
 14  AC7..00           Other intestinal helminthiases       0       4    4.00      0.05 
 15  B6...00 Malignant neoplasm of lymphatic and haemopoietic tissue       0       4    4.00      0.05 
 16  L46..00 Obstetric breast and lactation disorders NOS       0       4    4.00      0.05 
 17  H52..00                             Pneumothorax       2       8    4.00      0.10 
 18  S8z..00   Open wound of head, neck and trunk NOS       2       8    4.00      0.10 
 19  L05..00                 Legally induced abortion       2       8    4.00      0.10 
 20  17...00                     Respiratory symptoms       1       4    4.00      0.05 
 
 
 
 
 
 
